Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population

International Journal of Cancer

Volumn 124, Issue 9, 2009, Pages 2172-2178

  Jin, Guangfu ^a   Miao, Ruifen ^a   Hu, Zhibin ^a   Xu, Lin ^b   Huang, Xinen ^b   Chen, Yijiang ^a   Tian, Tian ^a   Wei, Qingyi ^c   Boffetta, Paolo ^d   Shen, Hongbing ^a,d  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

MMP; NSCLC; Polymorphisms; Survival

Indexed keywords

ARGININE; GELATINASE A; GELATINASE B; GLUTAMINE; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; STROMELYSIN; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; CHINA; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 63449112390     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24190     Document Type: Article

References (51)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 29094960)
2. Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005;14:243-250
3. Yang L, Parkin DM, Li LD, Chen YD, Bray F. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 2004;90:2157-2166
4. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-856 (Pubitemid 41746029)
5. Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL, Vaughan TL. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003;12:527-533
6. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-2601 (Pubitemid 41103746)
7. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR. p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002;94:681-690 (Pubitemid 34552489)
8. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270 (Pubitemid 27371946)
9. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43:42-51.
10. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34. (Pubitemid 43723979)
11. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-239
12. Mihaylova Zh, Ludovini V, Gregorg V, Floriani I, Pistola L, Toffaneti F, Ferraldeschi M, Spreafico A, Ceresoli GL, Bellet M, Darwish S, Tonato M, et al. Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. J BUON 2007;12:105-111
13. Guo CB, Wang S, Deng C, Zhang DL, Wang FL, Jin XQ. Relationship between matrix metalloproteinase 2 and lung cancer progression. Mol Diagn Ther 2007;11:183-192 (Pubitemid 46983410)
14. Laack E, Köhler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, Niestroy A, Dahlmann N, Peters A, Berger J, Fiedler W, Hossfeld DK. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13:1550-1557 (Pubitemid 35331452)
15. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 2001;61:7825-7829 (Pubitemid 33049371)
16. Fang S, Jin X, Wang R, Li Y, Guo W, Wang N, Wang Y, Wen D, Wei L, Zhang J. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 2005;26:481-486 (Pubitemid 40246571)
17. Zhou Y, Yu C, Miao X, Wang Y, Tan W, Sun T, Zhang X, Xiong P, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 2005;26:1117-1121 (Pubitemid 41214305)
18. Su L, Zhou W, Park S, Wain JC, Lynch TJ, Liu G, Christiani DC. Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:567-570 (Pubitemid 40489196)
19. Yu C, Pan K, Xing D, Liang G, Tan W, Zhang L, Lin D. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 2002;62:6430-6433 (Pubitemid 35364100)
20. Hu Z, Huo X, Lu D, Qian J, Zhou J, Chen Y, Xu L, Ma H, Zhu J, Wei Q, Shen H. Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin Cancer Res 2005;11:5433-5439 (Pubitemid 41060818)
21. Grieu F, Li WQ, Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 2004;88:197-204. (Pubitemid 40137297)
22. Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 2006;95:65-72. (Pubitemid 43228082)
23. Lei H, Hemminki K, Altieri A, Johansson R, Enquist K, Hallmans G, Lenner P, Försti A. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 2007;103:61-69 (Pubitemid 46653260)
24. Shin A, Cai Q, Shu XO, Gao YT, Zheng W. Genetic polymorphisms in the matrix metalloproteinase 12 gene (MMP12) and breast cancer risk and survival: the Shanghai Breast Cancer Study. Breast Cancer Res 2005;7:506-512 (Pubitemid 39665456)
25. Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E, Scorza R. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 2001;7:2344-2346 (Pubitemid 32751634)
26. Xu E, Lai M, Lv B, Xing X, Huang Q, Xia X. A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun 2004;324:999-1003. (Pubitemid 39361607)
27. Zinzindohoué F, Lecomte T, Ferraz JM, Houllier AM, Cugnenc PH, Berger A, Blons H, Laurent-Puig P. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res 2005;11:594-599 (Pubitemid 40116884)
28. Xing LL, Wang ZN, Jiang L, Zhang Y, Xu YY, Li J, Luo Y, Zhang X. Matrix metalloproteinase-9-1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. World J Gastroenterol 2007;13:4626-4629 (Pubitemid 47455246)
29. Kubben FJ, Sier CF, Meijer MJ, van den Berg M, van der Reijden JJ, Griffioen G, van de Velde CJ, Lamers CB, Verspaget HW. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer 2006;95:744-751 (Pubitemid 44373491)
30. Heist RS, Marshall AL, Liu G, Zhou W, Su L, Neuberg D, Lynch TJ, Wain J, Christiani DC. Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin Cancer Res 2006;12:5448-5453 (Pubitemid 44497260)
31. Rollin J, Régina S, Vourc'h P, Iochmann S, Bléchet C, Reverdiau P, Gruel Y. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 2007;56:273-280
32. Conde L, Vaquerizas JM, Dopazo H, Arbiza L, Reumers J, Rousseau F, Schymkowitz J, Dopazo J. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res 2006;34:W621-5. (Pubitemid 44529845)
33. Ke X, Collins A, Ye S. PIRA PCR designer for restriction analysis of single nucleotide polymorphisms. Bioinformatics 2001;17:838-839 (Pubitemid 32970482)
34. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-442 (Pubitemid 38443646)
35. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174 (Pubitemid 37328786)
36. Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005;1755:37-69. (Pubitemid 40720240)
37. Koç M, Ediger D, Budak F, Karadaǧ M, Oral HB, Uzaslan E, Ege E, Gözü RO. Matrix metalloproteinase-9 (MMP-9) elevated in serum but not in bronchial lavage fluid in patients with lung cancer. Tumori 2006;92:149-154 (Pubitemid 43835975)
38. Shou Y, Hirano T, Gong Y, Kato Y, Yoshida K, Ohira T, Ikeda N, Konaka C, Ebihara Y, Zhao F, Kato H. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in nonsmall-cell lung cancer. Br J Cancer 2001;85:1706-1712 (Pubitemid 34081517)
39. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, Chu SC. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354:91-99 (Pubitemid 40320678)
40. Bodey B, Bodey B, Jr, Gröger AM, Siegel SE, Kaiser HE. Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung. In Vivo 2001;15:175-180 (Pubitemid 32328192)
41. Ondo K, Sugio K, Yamazaki K, Yamaguchi M, Yano T, Yoshino I, Maehara Y. The significance of serum active matrix metalloproteinase-9 in patients with non-small cell lung cancer. Lung Cancer 2004;46:205-213 (Pubitemid 39330415)
42. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000;6:2349-2355 (Pubitemid 30399202)
43. Mihaylova Zh, Ludovini V, Gregorg V, Floriani I, Pistola L, Toffaneti F, Ferraldeschi M, Spreafico A, Ceresoli GL, Bellet M, Darwish S, Tonato M, et al. Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. J BUON 2007;12:105-111
44. Awakura Y, Ito N, Nakamura E, Takahashi T, Kotani H, Mikami Y, Manabe T, Kamoto T, Habuchi T, Ogawa O. Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett 2006;241:59-63.
45. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, Watkins H, Henney AM. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99:1788-1794 (Pubitemid 29181405)
46. Murphy G, Knäuper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol 1997;15:511-518
47. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet 1999;105:418-423
48. Joos L, He JQ, Shepherdson MB, Connett JE, Anthonisen NR, Paré PD, Sandford AJ. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002;11:569-76; Erratum in: Hum Mol Genet 2003;12:803-804 (Pubitemid 34257493)
49. Wyatt CA, Coon CI, Gibson JJ, Brinckerhoff CE. Potential for the 2G single nucleotide polymorphism in the promoter of matrix metalloproteinase to enhance gene expression in normal stromal cells. Cancer Res 2002;62:7200-7202 (Pubitemid 36025238)
50. Hettiaratchi A, Hawkins NJ, McKenzie G, Ward RL, Hunt JE, Wakefield D, Di Girolamo N. The collagenase-1 (MMP-1) gene promoter polymorphism - 1607/2G is associated with favourable prognosis in patients with colorectal cancer. Br J Cancer 2007;96:783-792 (Pubitemid 46376634)
51. Rutter JL, Mitchell TI, Butticè G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58:5321-5325 (Pubitemid 28551108)